 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Momenta Pharmaceuticals to Present at the MBC Mass Opportunities Biotechnology Investment ConferencePress Release October 26, 2005 CAMBRIDGE, Mass., October 26, 2005 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. , a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today t hat Alan L. Crane, President and Chief Executive Officer, will present at the MBC Mass Opportunities Biotechnology Investment Conference on Thursday, November 3, 2005 at 11:00 am EST at the Hilton at Logan Airport, Boston, MA. About Momenta: Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of novel drugs, the improvement of existing drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of complex and biologic drug products. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox(R). Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA. To receive additional information about Momenta, please visit our website at http://www.momentapharma.com, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners. Contact: Michael A. Lawless Momenta Pharmaceuticals, Inc. 617-395-5189 CONTACT: Michael A. Lawless of Momenta Pharmaceuticals, Inc.,+1-617-395-5189
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page